| Literature DB >> 26377232 |
Hui Lin1,2,3, Glenn A Jackson3,4,5, Yuan Lu2,3, Sara K Drenkhahn2,3, Korey J Brownstein2,3,6, Nicholas J Starkey2,3, William R Lamberson3,7, Kevin L Fritsche3,7, Valeri V Mossine2,3, Cynthia L Besch-Williford3,4, William R Folk2,3, Yong Zhang1, Dennis B Lubahn2,3.
Abstract
Sutherlandia frutescens is a medicinal plant, traditionally used to treat various types of human diseases, including cancer. Previous studies of several botanicals link suppression of prostate cancer growth with inhibition of the Gli/hedgehog (Gli/Hh) signaling pathway. Here we hypothesized the anti-cancer effect of S. frutescens was linked to its inhibition of the Gli/Hh signaling in prostate cancer. We found a dose- and time-dependent growth inhibition in human prostate cancer cells, PC3 and LNCaP, and mouse prostate cancer cell, TRAMP-C2, treated with S. frutescens methanol extract (SLE). We also observed a dose-dependent inhibition of the Gli-reporter activity in Shh Light II and TRAMP-C2QGli cells treated with SLE. In addition, SLE can inhibit Gli/Hh signaling by blocking Gli1 and Ptched1 gene expression in the presence of a Gli/Hh signaling agonist (SAG). A diet supplemented with S. frutescens suppressed the formation of poorly differentiated carcinoma in prostates of TRAMP mice. Finally, we found Sutherlandioside D was the most potent compound in the crude extract that could suppress Gli-reporter in Shh Light II cells. Together, this suggests that the S. frutescens extract may exert anti-cancer effect by targeting Gli/Hh signaling, and Sutherlandioside D is one of the active compounds.Entities:
Keywords: Sutherlandia frutescens; prostate cancer; sonic hedgehog
Mesh:
Substances:
Year: 2015 PMID: 26377232 PMCID: PMC4713350 DOI: 10.1002/cbin.10544
Source DB: PubMed Journal: Cell Biol Int ISSN: 1065-6995 Impact factor: 3.612